Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose radiotherapy plus immuno-chemotherapy conversion therapy for locally advanced esophageal squamous cell carcinoma (ESCC-LDR-02)
ChiCTR2500115140Phase 2Not yet recruiting
- Sponsor
- Army Medical Center of PLA
- Start
- Dec 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and carboplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Army Medical Center of PLA. Primary endpoint: R0 resection rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
paclitaxelcarboplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500115140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115140.